Vimarsana
Biggest News Aggregation in the World

Page 4 - Lai Wang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lai Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lai Wang Today - Breaking & Trending Today

BEIGENE, LTD. : Stock Market News and Information | BGNE| US07725L1026 - Vimarsana News

BEIGENE, LTD. : Stock Market News and Information | BGNE| US07725L1026

BEIGENE, LTD. : News, information and stories for BEIGENE, LTD. | Nasdaq: BGNE | Nasdaq

BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China - Vimarsana News

BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China

NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression BeiGene (NASDAQ: BGNE; HKEX:

China NMPA accepts BeiGene's sBLA for hepatocellular carcinoma - Vimarsana News

China NMPA accepts BeiGene's sBLA for hepatocellular carcinoma

The China NMPA has accepted BeiGene’s supplemental biologics license application (sBLA) for tislelizumab to treat hepatocellular carcinoma (HCC).

Related Topics:
Lai Wang
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab - Vimarsana News

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China - Vimarsana News

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

Submission seeks marketing authorization for first-line use in combination with chemotherapy in advanced esophageal squamous cell carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global